Under the Obama Administration, The Toxic Substances Control Act (TSCA) was updated to give the Environmental Protection Agency (EPA) more authority to ban asbestos completely in the United States. The carcinogen was originally banned in 1989, but by 1991 the ruling was over-turned. Anti-asbestos advocates have been fighting ever since[…]
From the blog
DENdritic Cell Immunotherapy for Mesothelioma (DENIM)
This study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) Purpose: of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to BSC alone.
Decrease in Survival Rate Among Those Who Receive Non-traditional Cancer Treatment
Complementary medicine and alternative medicine may sound one in the same, but are vastly different in how each is used, and varying results often make people wary of its true effectiveness. Alternative medicine is atypical, and not used with any sort of mainstream treatment. Complementary medicine, sometimes referred to as[…]
New Surgical Technique Illuminates Previously Undetected Mesothelioma Tumors
In addition to chemotherapy, radiation therapy, and immunotherapy, those suffering from mesothelioma also have the option for surgery (if they are physically able). Surgery is one of the better options for mesothelioma patients because it can remove most if not all the cancer; however, often times since the cancer is[…]
Osimertinib In EGFR Mutant Lung Cancer
This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation.
The names of the study drug involved in this study is:
– Osimertinib (Tagrisso)
Metal-based Compound May Reduce Tumor Size in Pleural, Peritoneal Mesothelioma
Mesothelial cells are found in the lining of major organs such as the chest or the abdomen. When asbestos fibers are inhaled or ingested, they slice through the soft tissue and become embedded in the lining of these organs. These fibers cause genetic mutations in the mesothelial cells which then[…]
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
Primary Outcome Measures Progression free survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Secondary Outcome Measures Overall survival [ Time Frame: 1 year ] To evaluate the efficacy of consolidation immunotherapy (Durvalumab) after durvalumab/Etoposide/cisplatin based-CCRT for LD-SCLC Safety[…]
Potential Breakthrough in Immunotherapy after Nivolumab Study Results
Immunotherapy treatments have once again made headlines, revolutionizing modern medicine and the way we have come to understand cancer treatment. The latest study results published in the American Journal of Case Reports, focuses on Opdivo (nivolumab), a type of check point inhibitor designed to stop immune cells from attacking the[…]
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
An open-label Phase I/II study, with a dose escalation part (Phase I) and a 2-arm randomized part (Phase II), in patients with recurrent SCLC.
Pneumothorax Helps Improve CT Scans, Early Detection for Mesothelioma Patients
Diagnosing mesothelioma in the early stages of the disease has proven to be a difficult task, and to better improve chances of survival from this aggressive cancer, the cancer needs to be found and treated quickly. Typical first steps in diagnosing mesothelioma are imaging techniques such as an x-ray, CT[…]
Skip to content